188 related articles for article (PubMed ID: 32718591)
1. Dual stimuli-responsive release of aptamer AS1411 decorated erlotinib loaded chitosan nanoparticles for non-small-cell lung carcinoma therapy.
Saravanakumar K; Sathiyaseelan A; Mariadoss AVA; Jeevithan E; Hu X; Shin S; Wang MH
Carbohydr Polym; 2020 Oct; 245():116407. PubMed ID: 32718591
[TBL] [Abstract][Full Text] [Related]
2. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles.
Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH
Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911
[TBL] [Abstract][Full Text] [Related]
3. AS1411 Aptamer-Decorated Biodegradable Polyethylene Glycol-Poly(lactic-co-glycolic acid) Nanopolymersomes for the Targeted Delivery of Gemcitabine to Non-Small Cell Lung Cancer In Vitro.
Alibolandi M; Ramezani M; Abnous K; Hadizadeh F
J Pharm Sci; 2016 May; 105(5):1741-1750. PubMed ID: 27039356
[TBL] [Abstract][Full Text] [Related]
4. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
5. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
6. Aptamer-Conjugated Chitosan-Anchored Liposomal Complexes for Targeted Delivery of Erlotinib to EGFR-Mutated Lung Cancer Cells.
Li F; Mei H; Xie X; Zhang H; Liu J; Lv T; Nie H; Gao Y; Jia L
AAPS J; 2017 May; 19(3):814-826. PubMed ID: 28233244
[TBL] [Abstract][Full Text] [Related]
7. Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer.
Mandal B; Mittal NK; Balabathula P; Thoma LA; Wood GC
Eur J Pharm Sci; 2016 Jan; 81():162-71. PubMed ID: 26517962
[TBL] [Abstract][Full Text] [Related]
8. Combination Chemotherapy of Lung Cancer - Co-Delivery of Docetaxel Prodrug and Cisplatin Using Aptamer-Decorated Lipid-Polymer Hybrid Nanoparticles.
Wu R; Zhang Z; Wang B; Chen G; Zhang Y; Deng H; Tang Z; Mao J; Wang L
Drug Des Devel Ther; 2020; 14():2249-2261. PubMed ID: 32606595
[TBL] [Abstract][Full Text] [Related]
9. Targeted delivery system using silica nanoparticles coated with chitosan and AS1411 for combination therapy of doxorubicin and antimiR-21.
Khatami F; Matin MM; Danesh NM; Bahrami AR; Abnous K; Taghdisi SM
Carbohydr Polym; 2021 Aug; 266():118111. PubMed ID: 34044928
[TBL] [Abstract][Full Text] [Related]
10. Aptamer-Functionalized and Backbone Redox-Responsive Hyperbranched Polymer for Targeted Drug Delivery in Cancer Therapy.
Zhuang Y; Deng H; Su Y; He L; Wang R; Tong G; He D; Zhu X
Biomacromolecules; 2016 Jun; 17(6):2050-62. PubMed ID: 27113017
[TBL] [Abstract][Full Text] [Related]
11. Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer.
Vaidya B; Parvathaneni V; Kulkarni NS; Shukla SK; Damon JK; Sarode A; Kanabar D; Garcia JV; Mitragotri S; Muth A; Gupta V
Int J Biol Macromol; 2019 Feb; 122():338-347. PubMed ID: 30401652
[TBL] [Abstract][Full Text] [Related]
12. Near-infrared/pH dual-responsive nanocomplexes for targeted imaging and chemo/gene/photothermal tri-therapies of non-small cell lung cancer.
Li Z; Zhu L; Liu W; Zheng Y; Li X; Ye J; Li B; Chen H; Gao Y
Acta Biomater; 2020 Apr; 107():242-259. PubMed ID: 32151700
[TBL] [Abstract][Full Text] [Related]
13. Poly(ester-thioether) microspheres co-loaded with erlotinib and α-tocopheryl succinate for combinational therapy of non-small cell lung cancer.
Cheng F; Peng X; Meng G; Pu Y; Luo K; He B
J Mater Chem B; 2020 Feb; 8(8):1728-1738. PubMed ID: 32022097
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and characterization of proanthocyanidin-chitosan nanoparticles: An assessment on human colorectal carcinoma HT-29 cells.
Mani S; Balasubramanian B; Balasubramani R; Chang SW; Ponnusamy P; Esmail GA; Arasu MV; Al-Dhabi NA; Duraipandiyan V
J Photochem Photobiol B; 2020 Sep; 210():111966. PubMed ID: 32711334
[TBL] [Abstract][Full Text] [Related]
15. MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery.
Sayari E; Dinarvand M; Amini M; Azhdarzadeh M; Mollarazi E; Ghasemi Z; Atyabi F
Int J Pharm; 2014 Oct; 473(1-2):304-15. PubMed ID: 24905777
[TBL] [Abstract][Full Text] [Related]
16. AS1411 aptamer/RGD dual functionalized theranostic chitosan-PLGA nanoparticles for brain cancer treatment and imaging.
Chauhan M; Sonali ; Shekhar S; Yadav B; Garg V; Dutt R; Mehata AK; Goswami P; Koch B; Muthu MS; Singh RP
Biomater Adv; 2024 Jun; 160():213833. PubMed ID: 38564997
[TBL] [Abstract][Full Text] [Related]
17. pH-controlled nucleolin targeted release of dual drug from chitosan-gold based aptamer functionalized nano drug delivery system for improved glioblastoma treatment.
Sathiyaseelan A; Saravanakumar K; Mariadoss AVA; Wang MH
Carbohydr Polym; 2021 Jun; 262():117907. PubMed ID: 33838795
[TBL] [Abstract][Full Text] [Related]
18. Smart drug delivery of p-Coumaric acid loaded aptamer conjugated starch nanoparticles for effective triple-negative breast cancer therapy.
Mariadoss AVA; Saravanakumar K; Sathiyaseelan A; Karthikkumar V; Wang MH
Int J Biol Macromol; 2022 Jan; 195():22-29. PubMed ID: 34861273
[TBL] [Abstract][Full Text] [Related]
19. Central composite designed formulation, characterization and in vitro cytotoxic effect of erlotinib loaded chitosan nanoparticulate system.
Pandey P; Chellappan DK; Tambuwala MM; Bakshi HA; Dua K; Dureja H
Int J Biol Macromol; 2019 Dec; 141():596-610. PubMed ID: 31494160
[TBL] [Abstract][Full Text] [Related]
20. Pegylated magnetic mesoporous silica nanoparticles decorated with AS1411 Aptamer as a targeting delivery system for cytotoxic agents.
Sakhtianchi R; Darvishi B; Mirzaie Z; Dorkoosh F; Shanehsazzadeh S; Dinarvand R
Pharm Dev Technol; 2019 Nov; 24(9):1063-1075. PubMed ID: 30654677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
